Home Tags PP Defence Therapeutics

PP Defence Therapeutics Related News

Accum™

Defence’s Accum™ technology effectiveness shown in published patent application

Defence Therapeutics has announced the publication of its new international (PCT) patent application. This demonstrates the effectiveness of Defence’s Accum™-based technology to intracellularly deliver...

Defence Therapeutics has reached the final stages of AccuTOXTM for its phase I clinical...

Defence Therapeutics has announced that it has reached the final stages of its AccuTOXTM Chemistry, Manufacturing, and Controls (CMC). A Canadian biopharmaceutical company specialised in...
pancreatic cancer

Defence Therapeutics initiate testing of ARM vaccine against pancreatic cancer

Defence Therapeutics has mandated the Transbiotech Biotechnology Research and Transfer Center to begin testing its cellular anti-cancer ARM vaccine against pancreatic cancer. Research from the...
AccuTOXTM

Defence Therapeutics completes AccuTOXTM preclinical efficacy studies

Defence Therapeutics has successfully completed all essential preclinical efficacy studies for the company’s AccuTOXTM programme. AccuTOXTM is one of Defence’s most advanced research and development...
trademark registration

Trademark registration approved by USPTO for DEFENCE THERAPEUTICS®

Defence Therapeutics has announced that the United States Patent and Trademark Office (USPTO) has granted registration for its trademark DEFENCE THERAPEUTICS®. This trademark is granted...
Vaccine enhancer technology

Defence Therapeutics granted US patent for vaccine enhancer technology

Discover how the issue of a patent will allow Defence Therapeutics' vaccine enhancer technology to be commercialised.
mRNA cancer vaccine

Defence Therapeutics’ mRNA cancer vaccine testing begins

Canadian biopharmaceutical specialist Defence Therapeutics has announced that testing of its revolutionary AccumTM-linked mRNA cancer vaccine has started. The performance of Defence’s AccumTM mRNA cancer...
mRNA cancer vaccine

Defence Therapeutics successfully develops ACCUMTM -mRNA cancer vaccine

Canadian biopharmaceutical pioneer Defence Therapeutics has revealed it has successfully conjugated mRNA molecules to AccumTM – a significant breakthrough that looks to enhance the...
AccuTOXTM

Defence to perform final AccuTOXTM preclinical study before Phase I cancer trial

Defence Therapeutics has announced it is performing a final preclinical study to validate the efficacy of AccuTOXTM combined with immune-checkpoint inhibitors before initiating a...
Defence Therapeutics and Orano agree to collaborate on radio-immuno-conjugates

Defence Therapeutics and Orano agree to collaborate on radio-immuno-conjugates

Defence Therapeutics Inc. is pleased to announce that they have signed a collaboration agreement with Orano to develop next-generation radio-immuno-conjugates using their intracellular targeting...
Defence advances to phase I clinical trials of the Accum technology

Defence advances to phase I clinical trials of the Accum technology

Defence Therapeutics Inc. is pleased to update its stakeholders on its completed achievements and outline the future milestones for AccumTM set for 2023. Over the...
Defence work with City of Hope in filing a new AccuTOX cancer programme

Defence work with City of Hope in filing a new AccuTOX cancer programme

Defence Therapeutics has teamed up with City of Hope to submit an application for the clinical trialling of their AccuTOX TM technology. The Canadian biopharmaceutical...
Defence Therapeutics begins manufacturing of it's ARM vaccine

Defence Therapeutics begins manufacturing of it’s ARM vaccine

Defence Therapeutics Inc., a Canadian biopharmaceutical company specialising in the development of immune-oncology vaccines and drug delivery technologies, is pleased to announce the start...
Defence Therapeutics begin toxicology study of intranasal AccutoxTM

Defence Therapeutics begin toxicology study on intranasal AccutoxTM

Defence Therapeutics Inc., a Canadian biopharmaceutical company specialising in the development of immune-oncology vaccines and drug delivery technologies is pleased to announce the start...
Defence Therapeutics has melanoma vaccine validated

Defence Therapeutics has melanoma vaccine validated

Defence Therapeutics Inc., a Canadian biopharmaceutical company specialising in the development of immune-oncology vaccines and drug delivery technologies, is pleased to report the validation...
Defence Therapeutics has US patent accepted for Accum

Defence Therapeutics has US patent accepted for Accum

Defence Therapeutics Inc, a Canadian biopharmaceuticals company primarily focussed on the development of novel immune-oncology vaccines and drug delivery technologies including Antibody Drug Conjugate...
Defence Therapeutics launch Accum-mRNA vaccine programme

Defence Therapeutics launch Accum-mRNA vaccine programme

Defence Therapeutics Inc., a Canadian biopharmaceutical company specialising in the development of immune-oncology vaccines and drug delivery technologies, is pleased to announce the advancement...

Defence’s novel Accutox intranasal reduces 50% of cancer nodules

Defence Therapeutics, a Canadian biopharmaceutical company specialising in the development of immune-oncology vaccines and drug delivery technologies, has just completed a pre-clinical study using...
Defence Therapeutics are using Accum technology in mRNA vaccines

Defence Therapeutics are using Accum technology in mRNA vaccines

Defence Therapeutics Inc., a Canadian biopharmaceutical company specialising in the development of immune-oncology vaccines and drug delivery technologies, is currently working on combining its...
Defence Therapeutics applies Accum technology to cancer vaccines

Defence Therapeutics to begin phase 1 trial for new anti-cancer treatment

Defence Therapeutics Inc., a Canadian biopharmaceutical company specialising in the development of immune-oncology vaccines and drug delivery technologies, is pleased to announce the successful...

Pin It on Pinterest